According to Zacks, “DelMar Pharmaceuticals, Inc. is involved in developing drug for orphan cancer indications. DelMar Pharmaceuticals, Inc. is headquartered in Vancouver, Canada. “
DMPI has been the subject of several other reports. Dawson James restated a buy rating on shares of DelMar Pharmaceuticals in a research note on Thursday, July 11th. Maxim Group initiated coverage on DelMar Pharmaceuticals in a research note on Friday, September 6th. They set a buy rating for the company. Finally, ValuEngine cut DelMar Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday, July 2nd.
NASDAQ DMPI traded up $0.07 on Wednesday, hitting $0.51. 64,871 shares of the company’s stock were exchanged, compared to its average volume of 186,033. The stock has a 50-day moving average of $0.57 and a 200-day moving average of $1.16. DelMar Pharmaceuticals has a 52 week low of $0.40 and a 52 week high of $7.00. The stock has a market cap of $1.32 million, a price-to-earnings ratio of -0.16 and a beta of 1.25.
DelMar Pharmaceuticals (NASDAQ:DMPI) last released its earnings results on Tuesday, September 10th. The company reported ($0.89) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.59). On average, equities research analysts anticipate that DelMar Pharmaceuticals will post -1.2 EPS for the current year.
About DelMar Pharmaceuticals
DelMar Pharmaceuticals, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy. Its product candidate includes VAL-083, a DNA-targeting agent, which is in Phase II clinical study for the treatment of glioblastoma multiforme (GBM), as well as other solid tumors, including ovarian cancer.
Recommended Story: What is the Rule of 72?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DelMar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.